Recent clinical trials and preclinical models proposed that IFNα plus an anti-PD-1 antibody was an efficient treatment strategy in cancer, emphasizing the great potential of IFNα-based combination ICB (15, 31, 32). Here, PDCD1 is linked to cancer.